Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19928505 | 0.76 | LMNA (0.42) | P2RX7HDAC6 | |
| SCHEMBL26348841 | 0.75 | FDPS (0.44) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL30572667 | 0.71 | ADORA1 (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL1868819 | 0.71 | FDPS (0.44) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL27960571 | 0.71 | FDPS (0.44) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL130453 | 0.71 | ADORA1 (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL23323404 | 0.70 | FDPS (0.63) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL20964641 | 0.70 | FDPS (0.41) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL28003435 | 0.69 | FDPS (0.43) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL6670287 | 0.68 | FDPS (0.42) | FDPSP2RX7HDAC6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954199-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10414737-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190031626-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20180162826-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-20170107187-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2017-04-20 | — | — | US | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9567337-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA LLC | 2017-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162826-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CB, PIK3CA, PIP4K2B | FDPS 712/4885P2RX7 3341/4885HDAC6 1645/4885 |
| US-10414737-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | PIK3CB, PIK3CA, PIP4K2B | FDPS 712/4885P2RX7 3341/4885HDAC6 1645/4885 |
| US-20190031626-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CB, PIK3CA, PIP4K2B | FDPS 712/4885P2RX7 3341/4885HDAC6 1645/4885 |
| US-10954199-B2 | Process methods for phosphatidylinositol 3-kinase inhibitors | PIK3CB, PIK3CA, PIP4K2B | FDPS 712/4885P2RX7 3341/4885HDAC6 1645/4885 |
| US-20170107187-A1 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CB, PIK3CA, PIP4K2B | FDPS 712/4885P2RX7 3341/4885HDAC6 1645/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | FDPS 1226/4885P2RX7 539/4885HDAC6 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.